Investigation of methods for preventing biofilm formation in peritoneal dialysis-related peritonitis

Investigation of methods for preventing biofilm formation in peritoneal dialysis-related peritonitis - Investigation of methods for preventing biofilm formation in peritoneal dialysis-related peritonitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038500

Enrollment

Registered

2019-11-11

Start date

2019-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End stage renal disease, Peritoneal dialysis-related peritonitis

Interventions

Clarithromycin treatment group: Clarithromycin 100 mg/day, po (at least 14 days), cefazolin sodium 1 g/day, iv, and isepamicin sulfate 0.1g/day (0.2g, 1st day), iv (at least 14 days) Standard treatme

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with peritoneal dialysis treatment Patients fulfilled at least two of the diagnosis criteria for peritoneal dialysis-related peritonitis (1. There were clinical signs of peritonitis such as abdominal pain, drainage turbidity. 2. The number of leukocytes in dialysis drainage after storage for at least two hours was more than 100/microL, and more than 50 percents of multinucleated leukocytes. 3. The result of drainage culture was positive) Patients who have obtained consent for hospitalization treatment for more than two weeks

Exclusion criteria

Exclusion criteria: Patients with a history of allergies to macrolide Patients complicated with exit infections and tunnel infections Patients with less than two weeks of treatment periods Patients suspected of biofilm formation due to peritonitis more than four weeks after previous peritonitis, the pathogenic microorganism is the same as previous one, or bacteria could not be detected. Patients without agreement on enrolment of this study Inappropriate patients judged by doctor

Design outcomes

Primary

Measure	Time frame
Peritonitis relapse rates, peritoneal dialysis catheter removal rates	—

Secondary

Measure	Time frame
Age, gender, weight, dialysis vintage, complications (diabetes, hypertension, heart disease), clinical symptoms at the time of peritonitis diagnosis (fever, abdominal pain, drainage turbidity, diarrhea), white blood cell counts in dialysis drainage at the time of peritonitis diagnosis, percentage of multinucleated leukocytes, blood tests at the time of peritonitis diagnosis (white blood cell count, neutrophil count, hemoglobin, albumin, CRP, etc.), causative bacteria, number of drained cells under treatment, peritonitis recurrence rate	—

Measure

Time frame

Age, gender, weight, dialysis vintage, complications (diabetes, hypertension, heart disease), clinical symptoms at the time of peritonitis diagnosis (fever, abdominal pain, drainage turbidity, diarrhea), white blood cell counts in dialysis drainage at the time of peritonitis diagnosis, percentage of multinucleated leukocytes, blood tests at the time of peritonitis diagnosis (white blood cell count, neutrophil count, hemoglobin, albumin, CRP, etc.), causative bacteria, number of drained cells under treatment, peritonitis recurrence rate

—

Countries

Japan

Contacts

Public ContactHisato Shima

Kawashima hospital Department of Kidney Disease

h.shima@khg.or.jp088-631-0110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026